KRAS and endometriosis: A systematic review and meta-analysis

Systematic review / meta-analysis OA: gold public-domain-us

Abstract

BackgroundEndometriosis is a chronic gynecological condition affecting approximately 10% of women of reproductive age worldwide. Accumulating molecular evidence suggests that endometriotic lesions harbor somatic oncogenic mutations, including activating mutations in the KRAS gene. However, the prevalence of KRAS mutations across endometriosis subtypes and their clinical significance remain poorly defined.ObjectivesThis systematic review and meta-analysis aimed to estimate the prevalence of somatic KRAS mutations in endometriosis, characterize variant allele frequencies, and evaluate associations with clinical outcomes, including recurrence, infertility, and malignant transformation.MethodsA comprehensive search of PubMed/MEDLINE, Embase, and Web of Science/Scopus was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (International Prospective Register of Systematic Reviews: CRD420261303629). Eligible studies included observational designs and molecular sequencing reports on endometriotic tissue. Pooled prevalence was estimated using a random-effects meta-analysis (DerSimonian-Laird model), with heterogeneity assessed using Cochran's Q and I2 statistics.ResultsSeven studies were included, covering deep infiltrating, ovarian, and superficial peritoneal endometriosis subtypes. The pooled KRAS mutation prevalence was 48% (95% confidence interval: 38%-58%), with substantial heterogeneity (I2 = 77%). Mutations were most frequent in deep infiltrating and ovarian lesions (50%-55%) compared with that in superficial peritoneal disease (∼30%-35%). Variant allele fractions were consistently low (<20%), reflecting clonal epithelial expansion. KRAS-positive patients demonstrated greater disease extent and surgical complexity, though associations with pain, infertility, and recurrence were not statistically significant.ConclusionPreliminary evidence suggests that KRAS mutations are common in endometriosis; however, findings should be interpreted cautiously owing to substantial study heterogeneity and limited available data. KRAS may hold biological significance as a biomarker; however, current evidence is insufficient to support routine clinical use.

My notes (saved in your browser only)

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Mutation Mutation Mutation Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins p21(ras) Female Female Female Gene Frequency Gene Frequency Gene Frequency Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Source provenance

europepmc
last seen: 2026-11-18T06:10:28.346261+00:00
openalex
last seen: 2026-11-18T06:02:33.299327+00:00
pubmed
last seen: 2026-11-18T06:04:25.516603+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine